Publication | Closed Access

Dextran-modified Quercetin-Cu(II)/hyaluronic acid nanomedicine with natural poly(ADP-ribose) polymerase inhibitor and dual targeting for programmed synthetic lethal therapy in triple-negative breast cancer

NanomedicineBreast OncologyEngineeringPolymer-drug ConjugateMedicineTherapeutic NanomaterialsDual TargetingDextran-modified Quercetin-cuBreast CancerTumor TargetingTriple-negative Breast CancerBiomedical EngineeringNano-drug DeliveryPharmacology